Document is current
Any future updates will be listed below
-
Authors
Maier, Lisa https://orcid.org/0000-0002-6473-4762
Goemans, Camille V. https://orcid.org/0000-0002-5564-1644
Wirbel, Jakob https://orcid.org/0000-0002-4073-3562
Kuhn, Michael https://orcid.org/0000-0002-2841-872X
Eberl, Claudia
Pruteanu, Mihaela
Müller, Patrick https://orcid.org/0000-0003-3290-8251
Garcia-Santamarina, Sarela https://orcid.org/0000-0002-0611-7918
Cacace, Elisabetta https://orcid.org/0000-0001-8239-0353
Zhang, Boyao https://orcid.org/0000-0002-2856-9376
Gekeler, Cordula https://orcid.org/0000-0001-9041-6672
Banerjee, Tisya https://orcid.org/0000-0003-1842-9350
Anderson, Exene Erin
Milanese, Alessio https://orcid.org/0000-0002-7050-2239
Löber, Ulrike https://orcid.org/0000-0001-7468-9531
Forslund, Sofia K. https://orcid.org/0000-0003-4285-6993
Patil, Kiran Raosaheb https://orcid.org/0000-0002-6166-8640
Zimmermann, Michael https://orcid.org/0000-0002-5797-3589
Stecher, Bärbel https://orcid.org/0000-0002-7445-5193
Zeller, Georg https://orcid.org/0000-0003-1429-7485
Bork, Peer https://orcid.org/0000-0002-2627-833X
Typas, Athanasios https://orcid.org/0000-0002-0797-9018
- License Information
-
More Information
Article History
Received: 6 November 2019
Accepted: 1 September 2021
First Online: 13 October 2021
Competing interests
: EMBL has filed a patent on using the antidotes identified in this study for prevention and/or treatment of dysbiosis and for microbiome protection (European patent application no. EP19216548.8). L.M., C.V.G., E.C. and A.T. are listed as inventors.
